This work serves as a starting point for further in vitro and in vivo characterization of these candidate biomarkers as predictors of de novo sensitivity or resistance to PI3K inhibitors, as pharmacodynamics markers, as well providing additional insights into the PI3K pathway and its role in cancer biology. Here, PIK3CA is linked to cancer.